Tag: Long acting injectable

Trevicta, a long-acting injectable for the maintenance treatment of schizophrenia, is administered just four times a year, providing an important therapeutic option for patients. This guide will detail exactly what strength is Trevicta and how its specific dosages are determined based on prior treatment with a monthly formulation.

Long-acting injectable (LAI) antipsychotics significantly improve medication adherence rates in patients with schizophrenia and schizoaffective disorder. This guide explores exactly **how long does paliperidone injection last** and the different formulations designed for extended, controlled release.

Nonadherence to daily oral antipsychotics is a leading cause of relapse and rehospitalization for individuals with schizophrenia. To address this critical issue, the long-acting injectable (LAI) medication Aristada offers significant benefits by providing a less frequent, more convenient treatment option.

Although they treat similar mental health conditions, Invega (paliperidone) is actually the primary active metabolite of risperidone (Risperdal). When considering **which is better, risperidone or Invega?**, it is crucial to examine their differences in metabolic pathways, side effect profiles, and dosing formulations, as these distinctions significantly impact individual treatment suitability.

The FDA approved the first long-acting injectable medication for HIV pre-exposure prophylaxis (PrEP) in late 2021. The primary brand-name for cabotegravir for PrEP, an integrase inhibitor that prevents HIV from establishing an infection, is Apretude.

The landscape of HIV treatment has evolved significantly, with new options offering improved convenience and efficacy. A key development is the emergence of long-acting injectables like CABENUVA, which presents a significant choice for patients alongside the highly effective daily oral regimen, Biktarvy.

Medication non-adherence rates in schizophrenia are estimated to be around 50%, making long-acting injectables a crucial treatment option [1.6.3]. While both medications contain the same active drug, the answer to 'Is Perseris the same as Risperdal Consta?' lies in their significant differences in administration and formulation.

In July 2024, pharmaceutical manufacturer Indivior announced its decision to stop all sales and marketing activities for its schizophrenia drug, Perseris® (risperidone). For patients currently on this long-acting injectable medication, understanding the implications of whether **Is Perseris still available?** is crucial for ensuring a seamless transition and continuity of care.

According to the FDA, the long-acting injectable Perseris is based on a daily oral risperidone dose. For patients switching to the monthly subcutaneous injection, understanding what is the oral equivalent of Perseris, which is the tablet or liquid form of risperidone (Risperdal), is key to managing treatment.

In the United States, adherence rates for oral antipsychotics can be as low as 40% to 60% [1.7.5]. To address this, long-acting injectables like Perseris offer a different approach, but a key question for healthcare providers is: **Is Perseris IM or subq?**